KRAS and RASopathy: The largely nonoverlapping spectra of somatic and germline KRAS mutations likely reflect the fact that — on one hand — widespread expression of the highly activated K-Ras proteins specified by cancer-associated somatic mutations severely compromises embryonic viability and — on the other — most RASopathy proteins are insufficiently potent to drive clonal outgrowth and malignant transformation.